Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei
NCT03976973Phase 2Unknown
- Sponsor
- Mucpharm
- Start
- May 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules, Replacement Enzymes
01
Overview
A Phase 2 trial of bromelain, acetylcysteine in pseudomyxoma peritonei (PMP), Pseudomyxoma peritonei (PMP), sponsored by Mucpharm. Status: unknown.
02
Drugs
bromelainacetylcysteine
03
Conditions
pseudomyxoma peritonei (PMP)Pseudomyxoma peritonei (PMP)
Beyond the preview
Go deeper on NCT03976973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976973.